Which patients with rheumatoid arthritis, spondyloarthritis, or juvenile idiopathic arthritis receive TNF-α antagonists in France? The CORPUS cohort study.
Fiche publication
Journal
Clinical and experimental rheumatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GUILLEMIN Francis
Tous les auteurs :
Saraux A, Benichou J, Guillevin L, Idbrik L, Job-Deslandre C, Sibilia J, Soudant M, Wendling D, Guillemin F
Lien Pubmed
Résumé
Limited information is available about the characteristics of patients with active inflammatory rheumatic diseases who start TNF-α antagonist therapy. Our objective was to assess TNF-α antagonist prescription patterns in this context in France.
Mots clés
Adolescent, Adult, Aged, Antirheumatic Agents, contraindications, Arthritis, Juvenile, diagnosis, Arthritis, Rheumatoid, diagnosis, Child, Drug Prescriptions, Drug Utilization Review, Female, France, Humans, Immunologic Factors, contraindications, Longitudinal Studies, Male, Middle Aged, Patient Selection, Practice Patterns, Physicians', trends, Prospective Studies, Severity of Illness Index, Spondylarthropathies, diagnosis, Time Factors, Treatment Outcome, Treatment Refusal, Tumor Necrosis Factor-alpha, antagonists & inhibitors, Young Adult
Référence
Clin. Exp. Rheumatol.. ;33(5):602-10